MBC BioLabs Announces New Partnership with Exodus

[San Francisco, CA – September 15, 2026] – MBC BioLabs is proud to welcome Exodus Bio as its newest partner, expanding the range of cutting-edge instrumentation available to our resident companies and reinforcing our commitment to helping life-science startups move faster.

EXODUS BIO will place its H-600 automated purification system on-site, giving MBC BioLabs residents access to label-free purification of extracellular vesicles (EVs), viral vectors, lipid nanoparticles (LNPs), and other nanoscale biologics. This access will help resident companies evaluate automated purification within their own research workflows.

Residents interested in using the H-600 are encouraged to contact EXODUS BIO to discuss their applications and schedule training.

EXODUS BIO develops automated purification systems for extracellular vesicles (EVs), viral vectors, lipid nanoparticles (LNPs), and other nanoscale biologics.

Its proprietary ultrasonic nanofiltration technology addresses the yield, purity, and throughput limitations of conventional purification methods—including ultracentrifugation, size-exclusion chromatography, and standard filtration. By integrating isolation, concentration, buffer exchange, and automated recovery, the EXODUS platform supports scalable, reproducible workflows from academic research and process development through high-throughput and GMP manufacturing.

Learn more at exodusbio.com or follow the company on Linkedin.

At MBC BioLabs, we believe that startups are the greatest force for positive change in the world. We are dedicated to helping biotech startups succeed – we like to say that we enable awesome. We offer flexible and cost-effective lab space, complete with operational support and millions of dollars’ worth of state-of-the-art equipment and instrumentation, along with a vibrant community of like-minded individuals tackling the world’s biggest problems.